Name: ACC 2021 Discussion: The STRENGTH Study @RadcliffeCardiology
Uploaded: 2026-09-22T08:17:00-05:00
Duration: 8 min 17 s
Description: ACC 2021 Discussion: The STRENGTH Study

ACC 2021 Discussion: The STRENGTH Study

Radcliffe Cardiology 2026-09-22 | ACC 2021 Discussion: The STRENGTH Study

RIO 2023 | Event Summary & Introducing the New Course Director for RIO 2024!

Radcliffe 2023-12-11 | Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

VIVA 23: STRIKE-PE: Indigo Aspiration System for PE

Radcliffe 2023-12-08 | We are joined online by Dr Ido Weinberg (Massachusetts General Hospital, US) to discuss the findings from the STRIKE-PE trial, sponsored by Penumbra.

This trial aimed to evaluate the real-world long-term outcomes of the Indigo Aspiration system in patients with intermediate and high-risk pulmonary embolism (PE).

Results showed a rapid, statistically significant improvement in RV/LV ratio and clinical measures, with safety maintained.

Interview Questions:
-What was the reasoning behind this trial
-Could you tell us about the Indigo Aspiration System?
-What was the patient population and study design?
-What are the key findings?
-What are your take-home messages
-What further study is needed?

Recorded remotely from Boston, 2023.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

A Look Back at 10 Years of Radcliffe

Radcliffe 2023-12-08 | Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

Highlights of Rhythm Interventions Online 2023 #RIOcongress2023

Radcliffe 2023-12-04 | View the RIO 2023 playlist: youtube.com/playlist?list=PLj4HFZt5uknp6aqLnMsg2HgTtHXIE9gJY&si=wr7cf3CXBLolLCYQ

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Presentation & Discussion: Gaps in Care for CIED Infection – How to Address Them

Radcliffe 2023-12-04 | Chair: Richard Schilling, London, UK
Panel: Jason Andrade, Vancouver, CA; Dan Atar, Oslo, NO; Carina Blomström-Lundqvist, Uppsala, SE

Presentation Session 1: Gaps in Care For CIED Infection – How to Address Them
Presenter: Carina Blomström-Lundqvist, Uppsala, SE

Presentation Session 2: Risk Factor Modification and AF Ablation – Working Together to Improve Outcomes
Presenter: Jason Andrade, Vancouver, CA

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Case & Discussion: Ablation of Paroxysmal AF Using a Single Catheter Solution

Radcliffe 2023-12-04 | Chair: Devi Nair, Jonesboro, US
Panel: Jason Andrade, Vancouver, CA; Julian Chun, Frankfurt, DE; Melanie Gunawardene, Hamburg, DE
Operator: Devi Nair, St Bernards Heart & Vascular Center, Jonesboro, US

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Case & Discussion: Taking Your S-ICD Box-Change to the Next Level: Tips & Tricks

Radcliffe 2023-12-04 | Chair: Jason Andrade, Vancouver, CA
Panel: Marta Acena Ramos, Dubai, UAE; Daniel Steven, Cologne, DE; Julia Vogler, Lübeck, DE
Operator: Julia Vogler, Universitätsklinikum Schleswig-Holstei, Lübeck, DE

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Live Case & Discussion: The Value of OT Near Field Mapping in Complex Atrial Tachycardia

Radcliffe 2023-12-04 | Chair: Devi Nair, Jonesboro, US
Panel: Jason Andrade, Vancouver, CA; Andreu Porta-Sánchez, Barcelona, ES; Daniel Steven, Cologne, DE
Operator: Javier Moreno Planas, Ramon and Cajal University Hospital, Madrid, ES

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Day 3 Introduction

Radcliffe 2023-12-04 | Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Day 2 Summary

Radcliffe 2023-12-01 | Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Presentation & Discussion: Biologically Plausible AI-Enhanced ECG Models

Radcliffe 2023-12-01 | Chair: Devi Nair, Jonesboro, US
Panel: Rahul Doshi, Scottsdale, US; Fu Siong Ng, London, UK; Vivek Reddy, New York, US
Presenter: Fu Siong Ng, London, UK

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Case & Discussion: Dual Chamber Leadless Pacing – A Paradigm Shift

Radcliffe 2023-12-01 | Chair: Devi Nair, Jonesboro, US
Panel: Rahul Doshi, Scottsdale, US; Fu Siong Ng, London, UK; Vivek Reddy, New York, US
Operator: Devi Nair, St Bernards Heart & Vascular Center, Jonesboro, US

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 223 | Live Case & Discussion: Persistent AF

Radcliffe 2023-12-01 | Chair: Devi Nair, Jonesboro, US
Panel: Moussa Mansour, Boston, US; Richard Schilling, London, UK; Atul Verma, Toronto, CA
Operators: Julian Chun & Boris Schmidt, CCB Markus Krankenhaus, Frankfurt, DE

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Case & Discussion: LA Appendage Exclusion Using a Revolutionary Rotational LAA Closure

Radcliffe 2023-12-01 | Chair: Richard Schilling, London, UK
Panel: Jason Andrade, Vancouver, CA; Luigi Di Biase, New York, US; Devi Nair, Jonesboro, US
Operator: Devi Nair, St Bernards Heart & Vascular Center, Jonesboro, US

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Live Case & Discussion: AF Ablation w PFA in Combination w Ultra-high Density 3D Mapping

Radcliffe 2023-12-01 | Chair: Julian Chun, Frankfurt, DE
Panel: Dhiraj Gupta, Liverpool, UK; Claire Martin, Cambridge, UK; Vivek Reddy, New York, US
Operator: Joaquin Osca Asensi, La Fé, Valencia, ES

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Live Case & Discussion: Future Options for AF Patients – One-Stop Shop PVI + LAAC

Radcliffe 2023-12-01 | Chair: Richard Schilling, London, UK
Panel: Andreas Metzner, Hamburg, DE; Devi Nair, Jonesboro, US; Arian Sultan, Cologne, DE
Operators: Julian Chun, Boris Schmidt & Stefano Bordignon, CCB Markus Krankenhaus, Frankfurt, DE

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Day 2 Introduction

Radcliffe 2023-11-30 | Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Day 1 Summary

Radcliffe 2023-11-29 | Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Case & Discussion: STAR Apollo Mapping System

Radcliffe 2023-11-29 | Chair: Devi Nair, Jonesboro, US
Panel: Moussa Mansour, Boston, US; Richard Schilling, London, UK; Atul Verma, Toronto, CA
Operators: Devi Nair & Richard Schilling, St Bernards Heart & Vascular Center, Jonesboro, US

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Live Case & Discussion: Persistent AF

Radcliffe 2023-11-29 | Chair: Devi Nair, Jonesboro, US
Panel: Moussa Mansour, Boston, US; Richard Schilling, London, UK; Atul Verma, Toronto, CA
Operators: Julian Chun & Boris Schmidt, CCB Markus Krankenhaus, Frankfurt, DE

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Case & Discussion: Advancing Efficiency in AF Mapping and Ablation

Radcliffe 2023-11-29 | Chair: Devi Nair, Jonesboro, US
Panel: Tarv Dhanjal, Coventry, UK; Richard Schilling, London, UK; Arian Sultan, Cologne, DE
Operators: Roland Tilz & Julia Vogler, University Heart Center, Lübeck, DE

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Case & Discussion: Hybrid Convergent Therapy for Long Standing Persistent AF

Radcliffe 2023-11-29 | Chair: Richard Schilling, London, UK
Panel: Syed Ahsan, London, UK; Mark La Meir, Brussels, BE; Roderick Tung, Phoenix, US
Operators: Wilber Su & Ken Fang, The University of Arizona College of Medicine, Phoenix, US

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Live Case & Discussion: Future Options for AF Patients – One-Stop Shop PVI + LAAC

Radcliffe 2023-11-29 | Chair: Richard Schilling, London, UK
Panel: Andreas Metzner, Hamburg, DE; Devi Nair, Jonesboro, US; Arian Sultan, Cologne, DE
Operators: Julian Chun, Boris Schmidt & Stefano Bordignon, CCB Markus Krankenhaus, Frankfurt, DE

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

RIO 2023 | Day 1 Introduction

Women as One @AHA23: Focus on Mentorship by Dr Cader & Dr Banerjee

Radcliffe 2023-11-28 | This video is produced in collaboration with Women as One.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

Women as One @AHA23: Mentoring Toolkit by Dr Cader & Dr Banerjee

Parallax | Ep 102: Nobility in Small Things with Cardiac Surgeon, Dr Craig R Smith

Radcliffe 2023-11-28 | In this week's episode of Parallax, Dr Ankur Kalra's guest is Dr Craig R Smith, Cardiac Surgeon and Chairman of the Department of Surgery at Columbia Presbyterian Hospital.

In 2020, The Wall Street Journal called Dr Smith the pandemic's most powerful writer. Each day throughout the COVID-19 crisis, Dr Smith provided the faculty and staff with updates on pandemic response and priorities, offering both vital information and unwavering support. This month, Dr Smith released his book, 'Nobility in Small Things: A Surgeon's Path’.

In this inspiring episode, Dr Smith delves into the story behind his book and the motivating circumstances that led him to become an author. Dr Kalra asks Dr Smith about his experience as a leader during the pandemic as a surgeon. Dr Smith shares the story of his unconventional journey into medicine, emphasizing how hard physical labor built his resilience and prepared him for his residency. Dr Kalra also asks about Dr Smith's experience as a surgeon for President Bill Clinton in 2004. We learn more about some of the highlights of Dr Smith's book and his advice for listeners aspiring to become writers.

Nobility in Small Things is available for purchase here: us.macmillan.com/books/9781250278…ityinsmallthings

Questions and comments can be sent to “podcast@radcliffe-group.com” and may be answered by Ankur in the next episode.
Guest: Dr Craig R SmithHost: @AnkurKalraMD and produced by: @RadcliffeCARDIO.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

Radcliffe 2023-11-24 | Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

VIVA 23: Wearable Non-Invasive Ultrasound for CLTI

Radcliffe 2023-11-23 | VIVA 23 - We are joined by Dr Mahmood Razavi (St. Joseph Heart & Vascular Center, Orange, CA, US) to discuss the findings from an early feasibility study of non-invasive therapeutic ultrasound (TUS) to treat chronic limb-threatening ischemia.

12 patients were enrolled in the trial, who had Rutherford class 3, 4 or 5 peripheral arterial disease. Participants received 30-40 TUS treatment sessions over two months.

Findings suggested that the therapy was tolerable and acceptable to patients. A 17% improvement in tissue oxygenation was also observed.

Interview Questions:

1. What are the unmet needs of PAD patients in 2023?
2. What was the patient population and study design?
3. What are the key findings?
4. What are your take-home messages?

Recorded remotely from Orange, 2023.

Editor: Jordan Rance
Video Specialist: Dan Brent

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

AHA 23: Preventive Cardiology in 2023

Radcliffe 2023-11-23 | AHA 23 - In this video, Dr Michael Honigberg (Massachusetts General Hospital, US) recaps the latest trends in preventive cardiology in 2023, both from the AHA scientific sessions and earlier in the year.

Topics covered in detail include:
SELECT
Advancements in Lipid Management
FDA Approval of Colchicine
CVRM Paradigm

Recorded at AHA 2023, Philadelphia.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

VEINS 23: VIVID: Venous Stent for the Iliofemoral Vein

Radcliffe 2023-11-22 | We are joined by Dr Mahmood Razavi (St. Joseph Heart & Vascular Center, US) to discuss the late-breaking findings of the VIVID trial, sponsored by Vesper Medical.

The VIVID Trial is a prospective, multicenter, single-arm, non-blinded clinical trial which aimed to investigate the efficacy and safety of the Vesper DUO Venous Stent System when compared to a pre-defined performance goal.

Safety results found that freedom from major adverse events was 98.7%, a statistically significant improvement over the performance goal. Efficacy results showed a patency rate of 90.2%, also a statistically significant finding.

Interview Questions:
-What was the reasoning behind this study?
-Could you tell us about the DUO Venous Stent System?
-What was the patient population and study design?
-What were the key findings?
-What are your take-home messages?
-What further study is needed, and what are the next steps?

Recorded remotely from Orange, 2023.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

AHA 23: 3 Trials That Will Change My Practice with Dr Purvi Parwani

Radcliffe 2023-11-22 | In this short video, Dr Purvi Parwani (Loma Linda University Health, US) shares the trials and data revealed at AHA 2023 that will impact her clinical practice.

Trials discussed in detail include:
POP-HT
CARDIA-SSBP Trial
CLEAR outcomes Study

Recorded on-site at AHA 23, Philadelphia.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

AHA 23 Late-Breaker Discussion: The SELECT Trial

Radcliffe 2023-11-22 | Investigator, Dr A Michael Lincoff (Cleveland Clinic, US) sat down with Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the SELECT trial (NCT03574597).

In this randomized, double-blind, parallel-group, placebo-controlled trial sponsored by Novo Nordisk, semaglutide was compared with a placebo in patients who have overweight or obesity and a history of cardiovascular disease. A total of 17,609 participants were enrolled by the investigators. In the investigator arm, participants received semaglutide injections as an adjunct to standard-of-care. The primary endpoint of this trial is the time to the first occurrence of a composite endpoint, which includes cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

Support: This is an independent discussion produced by Radcliffe Cardiology.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

Impactful trials at #aha23 #hypertension #clinicaltrials

Radcliffe 2023-11-22 | Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

Impactful results at #aha23 #clinicaltrials

VIVA 23: DETOUR 1 and DETOUR2: PQ Bypass System for Percutaneous Femoropopliteal Bypass

Radcliffe 2023-11-22 | We are joined virtually by Dr Sean Lyden (Cleveland Clinic, US) to discuss the findings of a pooled analysis of the DETOUR1 and DETOUR2 studies, which clinically investigated a device intended to improve blood flow in patients with peripheral arterial disease due to femoropopliteal chronic total occlusions.

Results suggest that at 2 years, the PQ bypass system is a safe and effective percutaneous treatment option for patients with longer, severely calcified lesions.

Interview Questions:
-What are the unmet needs for PAD patients with symptomatic femoropoliteal chronic total occlusions?
-Could you tell us about the unique features of the PQ Bypass System?
-What was the study design and patient population?
-What were the key results?
-What are your take-home messages?
-What further study is needed?

Recorded remotely from Ohio, 2023.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

TCT 23: 5 Trials That Will Change My Practice

Radcliffe 2023-11-22 | We are joined by Dr Bernardo Cortese (Ospedale Fate bene Fratelli, IT) for a concise and insightful summary of the late-breaking trials that are expected to have an impact on structural heart disease care.

Trials covered in detail include:
PARTNER 3
Evolut Low Risk
LIFE-BTK
AGENT-IDE
TRANSFORM I

Recorded remotely from Milano, 2023.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

TCT 23: 5Y Outcomes From the PARTNER 3 Low-Risk Trial

Radcliffe 2023-11-22 | In this short virtual interview, we are joined by Dr Martin B Leon (Columbia University Medical Center, US) to discuss the 5-year outcomes from Edwards' PARTNER 3 low-risk trial (NCT02675114).

PARTNER 3 is a randomized, prospective, multicenter trial that aimed to determine the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with severe calcific aortic stenosis with low operative risk for aortic valve replacement. 1000 patients were enrolled in the trial, and were randomized to receive either TAVR with the SAPIEN 3 valve, or a commedically available surgical bioprosthetic valve.

Results showed that death, strokes and cardiac rehospitalisation was reduced across 5 years with both TAVR and surgery, though the delta showed preference towards TAVR.

Interview Questions:

What are the unmet needs in TAVR patients in 2023?
Could you tell us a bit about the SAPIEN 3 Valve and its features?
What was the patient population and study design?
What are the main findings?
What conclusions can be drawn?
What further study is still needed?
Recorded remotely from New York, 2023.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

AHA 23: ORFAN: AI Technology to Improve Risk Stratification of Patients without CAD Undergoing CCTA

Radcliffe 2023-11-21 | In this brief interview, we are joined by Prof Charalambos Antoniades (Oxford University, UK) to discuss the ORFAN trial, sponsored by the University of Oxford.

ORFAN is a prospective, multicenter, observational study that collected CT scans, biological material and outcomes data to develop and validate biomarkers of cardiometabolic risk. The registry included 250000 unselected consecutive patients at participating centres. The study combines imaging data and patient demographics to improve new or existing image analysis algorithms and software tools.

Findings showed that in patients undergoing CTCA had 2x more heart attacks and cardiac deaths in those without obstructive CAD a compared to those with obstructive CAD. Measuring coronary inflammation predicts fatal and non-fatal cardiac events independent from clinical risk scores and CT interpretation. New AI-driven risk classification changes risk-driven management in 40% of patients.

Questions:
-What is the aim of the ORFAN registry?
-Can you tell us about the AI algorithm used in this study?
-What was the study design and the baseline characteristics of the study cohort?
-What are the findings?
-What conclusions can be made? What are the limitations of this registry?
-What advancements can we expect in the next 5 years as AI continues to impact the field of medicine?

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

Support: This is an independent interview conducted by Radcliffe Cardiology.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

AHA 23 Late-Breaker Discussion: Hypertension Treatment in Nigeria Program

Radcliffe 2023-11-21 | Investigator Dr Dike Bevis Ojji (University of Abuja, NG) talks with Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) about the Hypertension Treatment in Nigeria Program (NCT04158154).

The aim of this study (Washington University School of Medicine) and employing an interrupted time series design, is to assess the implementation and evaluation of a culturally- and contextually-adapted intervention package based on the Kaiser Permanente Northern California and World Health Organization HEARTS programs for diagnosing and treating hypertension in primary health centers in Abuja, Nigeria. The study enrolled 57,600 participants over the age of 18 with elevated blood pressure measured by a healthcare professional.

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

This is an independent discussion produced by Radcliffe Cardiology.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

AHA 23: 3 Trials That Will Change My Practice with Dr Dipti Itchhaporia

Radcliffe 2023-11-21 | AHA 23 - Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, US), interventional cardiologist and Past President of the American College of Cardiology (ACC) highlights the top three late-breaking science trials from the 2023 AHA Scientific Sessions with the potential to change medical practices.

Trials discussed in detail include:
SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
ARIES-HM3: Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure
ORBITA-2: A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina

Recorded on-site at AHA Scientific Sessions 23, Philadelphia.

Editor: Mirjam Boros
Videographer: Daniel Brent

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

AHA 23: KABUKI: Edoxaban in Patients with Chronic Thromboembolic Pulmonary Hypertension

Radcliffe 2023-11-20 | Dr Kazuya Hosokawa and Dr Abe Kotaro (Kyushu University Hospital, JP) join us to share the findings of the KABUKI trial (NCT04730037). The aim of KABUKI (Daiichi Sankyo) is to assess whether edoxaban, a direct factor Xa inhibitor, is noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary hypertension (CTEPH).

This investigator-initiated, multicenter, phase 3, randomized, single-blind, double-dummy, parallel-group study enrolled 74 patients. Eligible patients were randomly assigned to either the edoxaban or warfarin group in a 1:1 ratio. The primary efficacy endpoint was the change in catheter-based PVR at 1 year compared to baseline, with secondary endpoints including clinical worsening of CTEPH, 6-minute walk distance, WHO functional class, and N-terminal pro-brain natriuretic peptide at 1 year. The trial was conducted in eight Japanese institutes within their cardiovascular and pulmonology medicine departments.

Findings demonstrated that edoxaban was noninferior to warfarin in preventing worsening of pulmonary hemodynamics in CTEPH patients who had undergone reperfusion treatment during the 48 weeks treatment. Symptomatic venous thromboembolism and clinically relevant bleeding events were shown to be as low as wafarin

Questions:
-What is the prevalence of chronic thromboembolic pulmonary hypertension (CTEPH), and what is the importance of the KABUKI trial?
-What is the existing evidence for the use of DOACs in CTEPH?
-What is the study design, and what are the baseline characteristics of the randomized patients?
-What are the findings?
-Were there any unexpected or surprising findings in the trial?
-What are the take-home messages for practice? How widely can the study's findings be applied on a global scale?

This is an independent interview conducted by Radcliffe Cardiology.

Recorded on-site at AHA 2023, Philadelphia

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

View from the Thoraxcenter: AHA 23 Late-breaking Science Wrap Up

Radcliffe 2023-11-20 | What's hot at #AHA23?

Join Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) as they review the latest late-breaking science data from AHA Scientific Sessions 2023.

They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research.

Trials Covered:

00:20 - DAPA-MI: Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack

06:30 - ORBITA-2: Percutaneous Coronary Intervention for Stable Angina: A Randomised, Placebo-Controlled Trial

12:39 - A Sub-Analysis of the Prospective ECLS-Shock Trial

16:13 - ARTESiA: Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

10:02 - SELECT: Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity Who Do Not Have Diabetes

We value your opinion! Share your feedback by commenting on this page or sending us an email at info@radcliffe-group.com.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

AHA 23: JEWEL-IDE: Jewel P-WCD in Pts at High Risk of Cardiac Arrest

Radcliffe 2023-11-20 | In this short interview, we are joined by Dr John Hummel (Ohio State University, US) to discuss the findings from the JEWEL-IDE study, which investigated the use of the Jewel patch-wearable cardioverter defibrillator (PWCD) system in participants who were at high risk for sudden cardiac arrest. This was a multicenter, prospective, single-arm trial, with 290 participants.

Findings suggest that Jewel is safe and effective, with a high number of patient saves, no deaths or serious adverse events. There was a high patient compliance and low false alarm rate, and the device was well-tolerated for extended prescription durations.

Questions:
-What are the unmet needs for patients at high risk for cardiac arrest?
-What was the study design and the patient population?
-Could you tell us a bit more about the JEWEL system?
-What were the key findings?
-What are your take-home messages?
-What further study is needed?

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

This is an independent interview conducted by Radcliffe Cardiology.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

AHA 23: Screening for Peripartum Cardiomyopathies Using an AI Enanced Digital Stethoscope

Radcliffe 2023-11-20 | We are joined by Dr Demilade Adedinsewo (Mayo Clinic, US) to discuss the findings from a study investigating the effectiveness of an artificial intelligence-enabled ECG (AI-ECG) for cardiomyopathy detection in an obstetric population.

In the intervention arm, the digital stethoscope correctly identified 92% of those with ejection fraction less than 50% and 100% of those with ejection fraction less than 40% .

Questions
1. What are the unmet needs for patients with pregnancy-related cardiomyopathy?
2. What was the patient population and study design?
3. What were your key findings?
4. What are your take-home messages?
5. What further research is needed, and what are the next steps?

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

Support: This is an independent interview conducted by Radcliffe Cardiology.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

AHA 23 Late-Breaker Discussion: DAPA-MI: Dapagliflozin in Pts With an Acute Heart Attack

Radcliffe 2023-11-20 | Investigator, Prof Stefan James, Prof Jonas Oldgren (Uppsala University, SE) and Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) discuss the findings of the DAPA-MI trial (NCT04564742).

This multicenter, parallel-group, registry-based, randomized, double-blind and placebo-controlled phase 3 trial (AstraZeneca) investigated the effect of dapagliflozin 10 mg vs placebo, given once daily in addition to standard of care therapy (SoC), on death, hospitalization for HF (HHF) and other cardiometabolic outcomes.

4017 patients were enrolled in the study which excluded participants with known diabetes.

Results presented at AHA 2023 showed that dapagliflozin demonstrated significant benefit in patients with acute MI and impaired left ventricular systolic dysfunction, without diabetes or CHF in regards to improvement in cardiometabolic outcomes as compared to placebo. This effect was consistent across all prespecified subgroups, with no new safety concerns. Clinical event rates were low with no significant difference between randomized groups.

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

Support: This is an independent interview produced by Radcliffe Cardiology.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

AHA 23: SPECIAL: Ultrasound-assisted Thrombolysis Vs Pulmonary Embolectomy for PE

Radcliffe 2023-11-20 | We are joined onsite by Prof Stefan Stortecky (Bern University Hospital, Bern, SE) to discuss the findings of the single centre SPECIAL trial that investigated ultrasound-assisted catheter-directed thrombolysis as compared to surgical pulmonary embolectomy for intermediate high or high risk pulmonary embolism.

Questions:
1. What is the reasoning behind this study?
2. What is the patient population and study design?
3. What are the key findings?
4. What are your take-home messages?
5. What further research is needed, and what are the next steps?

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

This is an independent interview conducted by Radcliffe Cardiology.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

AHA 23: Nicotinamide Riboside in PAD for Improved Walking

Radcliffe 2023-11-15 | Dr Mary McDermott (Northwestern University, US) joins us to summarize the key findings from a randomized clinical trial investigating whether nicotinamide riboside (NR) can enhance walking performance in patients with peripheral artery disease (PAD).

Investigators randomized 90 patients with ABI ≤ 0.90 at baseline into three groups - one receiving 100mg daily NR with 125mg resveratrol, one receiving 100mg daily NR alone, and one receiving placebo.

The results showed that NR significantly improved six-minute walk distance and treadmill walking time in PAD. Resveratrol did not enhance the effects of NR, with similar findings between patients who had received NR and resveratrol and NR alone. Despite this, it must be noted that there was a high-non-adherence rate in the NR and resveratrol group.

Questions:
-What is the rationale for NR supplementation in patients with PAD?
-What was the study design and outcome measures?
-What are the baseline characteristics of the randomized patients?
-What is the data presented at AHA 2023?
-Were there any unexpected or surprising results in the trial?
-What are the take-home messages?
-What are the next steps?

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

This is an independent interview conducted by Radcliffe Cardiology.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

AHA 23: SUPER LIPID

Radcliffe 2023-11-13 | We are joined by Dr Alexander Fanaroff (Penn Medicine, US) to discuss the findings from a cluster randomised trial of automated referral to centralised pharmacy services for evidence-based statin initiation in high-risk patients.

Gaps have been observed in evidence-based statin prescriptions, where more than 50% of US adults with an indication for atherosclerotic cardiovascular disease are not prescribed statins at the guideline-recommended intensity. Where physicians have limited time to cover preventative needs in-office visits, pharmacists could be used to increase statin prescriptions in appropriate patients.

The SUPER LIPID program aims to test two strategies for the integration of centralised pharmacy services for lipid management into clinician workflow; an interruptive pop-up notification strategy, and a non-visit based asynchronous strategy. Two parallel clinical trials were performed in 10 internal medicine and family medicine clinics in Philadelphia.

Findings suggested that an asynchronous strategy increased prescriptions of any statin by 16% as compared to standard care, and appropriate dose statin by 17%. The interruptive notification strategy had a smaller effect on statin prescriptions, and no effect on appropriate dose prescription, suggesting that a centralised asynchronous model could be an effective approach to increasing statin prescription for high-risk patients.

Questions:
-What is the reasoning behind this trial?
-What was the patient population and study design?
-What are the key findings?
-What are your take-home messages?
-Were there any unexpected or surprising results in the trial?
-What are the next steps?

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO

AHA 23: ECLS-SHOCK: Impact of Cardiac Arrest on the Efficacy of ECLS Patients

Radcliffe 2023-11-12 | We are joined on-site by Prof Uwe Zeymer (Klinikum Ludwigshafen, Ludwigshafen, DE) to discuss the findings from a sub-analysis of the ECLS-SHOCK trial.

This sub-analysis investigates the impact of cardiac arrest before randomisation on the efficacy of ECLS in patients with infarct-related cardiogenic shock. Investigators enrolled 420 patients with acute MI and cardiogenic shock across 41 centers. The primary outcome was 30-day mortality.

Investigators reached 49% mortality in the control group, however there was no reduction in mortality with implantation of a VA-ECMO device at 47.8%. Bleeding and vascular complications were higher regardless of whether patients had cardiac arrest before randomisation.

Interview Questions:
-What is the reasoning behind this sub-analysis?
-What was the patient population and study design?
-What were your key findings?
-What are your take-home messages?
-What further study is needed, and what are the next steps?

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

Support: This is an independent interview conducted by Radcliffe Cardiology.

Visit Radcliffe Cardiology: radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO